The natural flavonoid morin demonstrates promise as a dual-function agent against hepatocellular carcinoma (HCC) and chronic liver disease. Preclinical studies indicate it counteracts toxin-induced liver injury by modulating oxidative stress and inflammation via pathways like Nrf2/HO-1 and NF-κB. In HCC, morin enhances the efficacy of cisplatin by suppressing PARP1-mediated protective autophagy and DNA repair, while concurrently mitigating the drug’s nephrotoxic side effects. This capacity to simultaneously combat tumor progression and protect normal tissues positions morin as a versatile therapeutic candidate. Its clinical translation will require formal validation in human studies and the development of advanced delivery systems to overcome restrictions in bioavailability.
Azhagu Madhavan Sivalingam (Tue,) studied this question.